Search Results - "Shemesh CS"

Metabolism of new drug modalities research advances – 2023 year in review.

Authors: Ma, Bin Argikar, Upendra A Cheruzel, Lionel et al.

Source: Drug Metabolism Reviews. Aug2024, Vol. 56 Issue 3, p223-246. 24p.

Biotransformation novel advances – 2021 year in review.

Authors: Khojasteh, S. Cyrus Argikar, Upendra A. Cho, Sungjoon et al.

Source: Drug Metabolism Reviews. Aug2022, Vol. 54 Issue 3, p207-245. 39p.

A novel oncolytic vaccinia virus with multiple gene modifications involved in viral replication and maturation increases safety for intravenous administration while maintaining proliferative potential in cancer cells.

Authors: Okita, Go Suenaga, Kiyotaka Sakaguchi, Masashi et al.

Source: PLoS ONE. 3/6/2025, Vol. 20 Issue 3, p1-19. 19p.

Tailored therapies for triple-negative breast cancer: current landscape and future perceptions.

Authors: Khan Y Rizvi S Raza A et al.

Source: Naunyn-Schmiedeberg's archives of pharmacology [Naunyn Schmiedebergs Arch Pharmacol] 2025 Aug; Vol. 398 (8), pp. 9425-9450. Date of Electronic Publication: 2025 Mar 03.

Publication Type: Journal Article; Review; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 0326264 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1912 (Electronic) Linking ISSN: 00281298 NLM ISO Abbreviation: Naunyn Schmiedebergs Arch Pharmacol Subsets: MEDLINE

Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors.

Authors: Huang W Stader F Chan P et al.

Source: Frontiers in pharmacology [Front Pharmacol] 2022 Sep 26; Vol. 13, pp. 974423. Date of Electronic Publication: 2022 Sep 26 (Print Publication: 2022).

Publication Type: Journal Article

Journal Info: Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE

The use of nanomaterials as drug delivery systems and anticancer agents in the treatment of triple-negative breast cancer: an updated review (year 2005 to date).

Authors: Ndongwe, Tanaka Zhou, Angel-Alberta Ganga, Nelisa Paidamwoyo et al.

Source: Discover Nano; 9/3/2024, Vol. 19 Issue 1, p1-24, 24p

An integrated approach to the characterization of immune repertoires using AIMS: An Automated Immune Molecule Separator.

Authors: Boughter, Christopher T. Meier-Schellersheim, Martin

Source: PLoS Computational Biology. 10/20/2023, Vol. 19 Issue 10, p1-26. 26p. 6 Graphs.

Cell-Based Vaccines: Frontiers in Medical Technology for Cancer Treatment.

Authors: Arjmand, Babak Alavi-Moghadam, Sepideh Khorsand, Golnar et al.

Source: Regenerative Engineering & Translational Medicine. Dec2024, Vol. 10 Issue 4, p480-499. 20p.

A lentiviral vector targeting a KRAS neoepitope for cancer immunotherapy.

Authors: Goloudina, Anastasia Le Chevalier, Fabien Authié, Pierre et al.

Source: Scientific Reports. 7/2/2025, Vol. 15 Issue 1, p1-17. 17p.

Lack of Pharmacokinetic Drug–Drug Interactions Between Bepirovirsen and Nucleos(t)ide Analogs.

Authors: Han, Kelong Youssef, Amir S. Magee, Mindy et al.

Source: Clinical Pharmacology in Drug Development. Apr2025, Vol. 14 Issue 4, p281-291. 11p.

Dose optimization of an adjuvanted peptide-based personalized neoantigen melanoma vaccine.

Authors: Valega-Mackenzie, Wencel Rodriguez Messan, Marisabel Yogurtcu, Osman N. et al.

Source: PLoS Computational Biology. 3/1/2024, Vol. 20 Issue 2, p1-24. 24p.

VSIG4⁺ tumor-associated macrophages mediate neutrophil infiltration and impair antigen-specific immunity in aggressive cancers through epigenetic regulation of SPP1.

Authors: Pan, Zongfu Chen, Jinming Xu, Tong et al.

Source: Journal of Experimental & Clinical Cancer Research (17569966). 2/7/2025, Vol. 44 Issue 1, p1-19. 19p.

Integrated Two-Analyte Population Pharmacokinetics Model of Patritumab Deruxtecan (HER3-DXd) Monotherapy in Patients with Solid Tumors.

Authors: Xu Y Lee M Joshi R et al.

Source: Clinical pharmacokinetics [Clin Pharmacokinet] 2025 Jun; Vol. 64 (6), pp. 943-957. Date of Electronic Publication: 2025 May 23.

Publication Type: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Country of Publication: Switzerland NLM ID: 7606849 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1926 (Electronic) Linking ISSN: 03125963 NLM ISO Abbreviation: Clin Pharmacokinet Subsets: MEDLINE

Folic acid-modified antigen-trapping nanoprobes for developing in situ tumor vaccines to inhibit metastasis and recurrence of ovarian cancer.

Authors: Zhong X Pu T Cheng Y et al.

Source: Journal of nanobiotechnology [J Nanobiotechnology] 2026 May 11; Vol. 24 (1). Date of Electronic Publication: 2026 May 11.

Publication Type: Journal Article

Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 101152208 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-3155 (Electronic) Linking ISSN: 14773155 NLM ISO Abbreviation: J Nanobiotechnology Subsets: MEDLINE

An integrated AI-driven vaccine design process: a systematic review of workflows from generative design to translational prediction.

Authors: Shafaati M Nikzadjamnani F Ghorbani M

Source: Immunologic research [Immunol Res] 2026 May 07; Vol. 74 (1). Date of Electronic Publication: 2026 May 07.

Publication Type: Journal Article; Systematic Review; Review

Journal Info: Publisher: Humana Press Country of Publication: United States NLM ID: 8611087 Publication Model: Electronic Cited Medium: Internet ISSN: 1559-0755 (Electronic) Linking ISSN: 0257277X NLM ISO Abbreviation: Immunol Res Subsets: MEDLINE

Immune checkpoint inhibitors in pediatric central nervous system tumors: biology, clinical experience, and translational pathways to precision immunotherapy.

Authors: Yenidogan I Tabori U Das A

Source: Journal of neuro-oncology [J Neurooncol] 2026 Mar 02; Vol. 177 (1). Date of Electronic Publication: 2026 Mar 02.

Publication Type: Journal Article; Review

Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 8309335 Publication Model: Electronic Cited Medium: Internet ISSN: 1573-7373 (Electronic) Linking ISSN: 0167594X NLM ISO Abbreviation: J Neurooncol Subsets: MEDLINE

Population pharmacokinetics of imetelstat, a first‐in‐class oligonucleotide telomerase inhibitor.

Authors: González‐Sales, Mario Lennox, Ashley L. Huang, Fei et al.

Source: CPT: Pharmacometrics & Systems Pharmacology. Jul2024, Vol. 13 Issue 7, p1264-1277. 14p.

Tumor cells inhibit the activation of ILC2s through up-regulating PD-1 expression.

Authors: Yin, Chaoyun Pa, Yani Li, Guangyu et al.

Source: Immunopharmacology & Immunotoxicology. Jun2024, Vol. 46 Issue 3, p417-423. 7p.

Advances in applications of siRNA in cancer therapy: challenges and opportunities.

Authors: Mehrparvar M Shabani S Oruji F et al.

Source: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2026 Jul 18. Date of Electronic Publication: 2026 Jul 18.

Publication Type: Journal Article; Review

Journal Info: Publisher: Country of Publication: Italy NLM ID: 101247119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1699-3055 (Electronic) Linking ISSN: 1699048X NLM ISO Abbreviation: Clin Transl Oncol Subsets: MEDLINE

Morusin shows potent antitumor activity for melanoma through apoptosis induction and proliferation inhibition.

Authors: Liu, Wei Ji, Yacong Wang, Feng et al.

Source: BMC Cancer. 6/29/2023, Vol. 23, p1-16. 16p.